[go: up one dir, main page]

FR16C0026I2 - Souches de virus herpetique pour therapie genique - Google Patents

Souches de virus herpetique pour therapie genique

Info

Publication number
FR16C0026I2
FR16C0026I2 FR16C0026C FR16C0026C FR16C0026I2 FR 16C0026 I2 FR16C0026 I2 FR 16C0026I2 FR 16C0026 C FR16C0026 C FR 16C0026C FR 16C0026 C FR16C0026 C FR 16C0026C FR 16C0026 I2 FR16C0026 I2 FR 16C0026I2
Authority
FR
France
Prior art keywords
hsv1
strain
hsv
gene therapy
virus strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0026C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovex Ltd
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0026(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0001475A external-priority patent/GB0001475D0/en
Priority claimed from GB0002854A external-priority patent/GB0002854D0/en
Priority claimed from GB0100288A external-priority patent/GB0100288D0/en
Priority claimed from GB0100430A external-priority patent/GB0100430D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of FR16C0026I1 publication Critical patent/FR16C0026I1/fr
Application granted granted Critical
Publication of FR16C0026I2 publication Critical patent/FR16C0026I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR16C0026C 2000-01-21 2016-06-15 Souches de virus herpetique pour therapie genique Active FR16C0026I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0001475A GB0001475D0 (en) 2000-01-21 2000-01-21 Virus strains
GB0002854A GB0002854D0 (en) 2000-02-08 2000-02-08 Virus strains
GB0100288A GB0100288D0 (en) 2001-01-05 2001-01-05 Virus strains
GB0100430A GB0100430D0 (en) 2001-01-06 2001-01-06 Virus strains
PCT/GB2001/000225 WO2001053505A2 (en) 2000-01-21 2001-01-22 Herpes virus strains for gene therapy

Publications (2)

Publication Number Publication Date
FR16C0026I1 FR16C0026I1 (ja) 2016-07-22
FR16C0026I2 true FR16C0026I2 (fr) 2018-04-27

Family

ID=27447756

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0026C Active FR16C0026I2 (fr) 2000-01-21 2016-06-15 Souches de virus herpetique pour therapie genique

Country Status (22)

Country Link
US (12) US7063835B2 (ja)
EP (4) EP1252323B1 (ja)
JP (6) JP4810042B2 (ja)
KR (2) KR100802403B1 (ja)
CN (2) CN1250732C (ja)
AT (2) ATE312189T1 (ja)
AU (2) AU2695101A (ja)
BE (1) BE2016C033I2 (ja)
BR (3) BRPI0107736B8 (ja)
CA (2) CA2398335C (ja)
CY (2) CY2016020I2 (ja)
DE (2) DE60115600T2 (ja)
DK (2) DK1252323T3 (ja)
ES (2) ES2233600T5 (ja)
FR (1) FR16C0026I2 (ja)
GB (2) GB2374873C (ja)
HK (2) HK1047451B (ja)
IL (4) IL150677A0 (ja)
LU (2) LU93100I2 (ja)
NL (2) NL300820I2 (ja)
PT (1) PT1252322E (ja)
WO (2) WO2001053505A2 (ja)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ES2233600T5 (es) * 2000-01-21 2009-06-22 Biovex Limited Cepas de virus del herpes.
AU2002306919B2 (en) 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP2007511216A (ja) * 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
AU2005228788B2 (en) * 2004-03-31 2010-12-02 Tomoki Todo Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
PT2516629T (pt) 2009-12-21 2016-07-07 The Brigham And Women`S Hospital Inc Vacinas de vírus herpes simplex
CN102146418B (zh) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
WO2011101912A1 (ja) * 2010-02-19 2011-08-25 国立大学法人東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
WO2011119628A2 (en) * 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
RS58146B1 (sr) * 2011-09-08 2019-02-28 Univ New York Onkolitički herpes simpleks virus i njegova terapeutska upotreba
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
JP6457940B2 (ja) 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
KR102242981B1 (ko) * 2013-07-17 2021-04-22 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
KR102458637B1 (ko) 2013-10-24 2022-10-24 암겐 인코포레이티드 주입기 및 조립 방법
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
CN106663139A (zh) 2014-06-03 2017-05-10 安姆根有限公司 用于远程处理由药物递送装置收集的数据的系统和方法
EP3943135A3 (en) 2014-10-14 2022-06-29 Amgen Inc. Drug injection device with visual and audible indicators
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
EP3250550B1 (en) 2015-01-26 2023-04-05 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
IL284375B (en) * 2015-04-30 2022-07-01 Psioxus Therapeutics Ltd Replication competent oncolytic group b adenovirus
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
MX2018007249A (es) 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
CN116059379A (zh) 2016-02-19 2023-05-05 复诺健生物科技加拿大有限公司 利用stat1/3抑制剂与溶瘤型疱疹病毒的组合物和方法
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
EP4212169A1 (en) 2016-03-25 2023-07-19 PeriphaGen, Inc. High-transducing hsv vectors
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins and CD80 variants and their uses
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3426272A4 (en) * 2016-04-26 2020-03-04 Salk Institute for Biological Studies ONCOLYTIC HSV-1 VIRUS THERAPIES WITH SPECIFIC KILLING OF OLD-DEPENDENT CARCINOMAS
WO2017190112A1 (en) 2016-04-29 2017-11-02 Virogin Biotech Canada Ltd Hsv vectors with enhanced replication in cancer cells
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032669A1 (en) 2016-08-01 2018-02-08 William Jia Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN119592523A (zh) 2016-08-29 2025-03-11 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
WO2018064762A1 (en) 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
EP3529361B1 (en) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
US20180169271A1 (en) 2016-12-21 2018-06-21 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
JP2020507349A (ja) 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
AU2018230546B2 (en) 2017-03-07 2024-03-21 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
US20200009204A1 (en) 2017-03-15 2020-01-09 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CA3053804A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
JP7386083B2 (ja) 2017-03-16 2023-11-24 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質及びその使用
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3600491B1 (en) 2017-03-28 2023-08-09 Amgen Inc. Plunger rod and syringe assembly system and method
CA3057157A1 (en) 2017-04-28 2018-11-01 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
CN106974942A (zh) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
IL312607B1 (en) 2017-08-03 2025-04-01 Amgen Inc Interleukin-21 Mutants and Treatment Methods
TW201912173A (zh) 2017-08-07 2019-04-01 美商安進公司 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
US20200308550A1 (en) 2017-09-11 2020-10-01 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
US20200353022A1 (en) 2017-10-27 2020-11-12 Merck Sharp & Dohme Corp. Compositions and methods for treating liver cancer
US11305026B2 (en) 2017-11-03 2022-04-19 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
CN111373032A (zh) 2017-11-24 2020-07-03 渥太华医院研究所 用于增强干扰素敏感性病毒的生产、生长、扩散或溶瘤和免疫治疗功效的组合物和方法
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
US11897924B2 (en) * 2018-03-28 2024-02-13 Bioxodes Anticoagulant fusion proteins and uses thereof
CN112368017A (zh) * 2018-05-01 2021-02-12 阿尔伯特爱因斯坦医学院 HSV-2-DELTA-gD疫苗及其生产和使用方法
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3801583A1 (en) * 2018-06-08 2021-04-14 The Board of Trustees of the University of Illinois Recombinant herpes simplex virus for cancer immunotherapy
WO2019241622A1 (en) * 2018-06-15 2019-12-19 Children's Hospital Medical Center Polypeptides, nucleic acid molecules, compositions, and related methods
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
CA3110529A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
TWI824026B (zh) 2018-10-05 2023-12-01 美商安進公司 具有劑量指示器之藥物遞送裝置
MX2021002791A (es) 2018-10-15 2021-05-12 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CA3116192A1 (en) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN113891934A (zh) 2018-11-21 2022-01-04 因达普塔治疗公司 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
AR117547A1 (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas
EP3921334A1 (en) * 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010458A (es) * 2019-03-05 2021-09-21 Amgen Inc Uso de virus oncoliticos para el tratamiento del cancer.
JP2022526094A (ja) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー 操作された単純ヘルペスウイルス－１（ｈｓｖ－１）ベクターおよびその使用
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023507989A (ja) * 2019-12-20 2023-02-28 クリスタル バイオテック インコーポレイテッド 気道及び／または肺への遺伝子送達のための組成物及び方法
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
US20220016191A1 (en) * 2020-07-16 2022-01-20 Massachusetts Institute Of Technology Simultaneous delivery of cancer treatment programs to tumor and immune cells
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN117320964A (zh) 2021-05-21 2023-12-29 美国安进公司 优化药物容器的灌装方案的方法
TW202313982A (zh) * 2021-08-20 2023-04-01 大陸商廣東東陽光藥業有限公司 Hsv病毒載體及其應用
WO2024038857A1 (ja) 2022-08-16 2024-02-22 具紀 藤堂 単純ヘルペスウイルスベクターを含む医薬組成物
WO2024251286A1 (zh) * 2023-06-08 2024-12-12 上海药明生物医药有限公司 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163949A (en) * 1990-03-02 1992-11-17 Bonutti Peter M Fluid operated retractors
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
GB9202933D0 (en) 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
EP0675961B1 (en) 1992-03-31 2002-11-27 Arch Development Corporation Treatment of tumorigenic disease with a modified HSV
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9423663D0 (en) * 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
NL9500216A (nl) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
DE69636068T2 (de) * 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. Virale zubereitungen, vektoren, immunogene und impfstoffe
IL118942A (en) 1995-07-27 2002-09-12 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP1314430A1 (en) 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB2322130B (en) 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
GB9704046D0 (en) 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
CA2323067A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
AU5467899A (en) 1998-08-07 2000-02-28 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
CA2356937A1 (en) 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
WO2000075292A1 (en) 1999-06-08 2000-12-14 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
GB9930419D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB0001476D0 (en) 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
ES2233600T5 (es) * 2000-01-21 2009-06-22 Biovex Limited Cepas de virus del herpes.
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
MX2018008413A (es) * 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.

Also Published As

Publication number Publication date
US20150232812A1 (en) 2015-08-20
LU93101I2 (fr) 2016-08-08
GB0219033D0 (en) 2002-09-25
JP4810042B2 (ja) 2011-11-09
US20200032219A1 (en) 2020-01-30
AU2695101A (en) 2001-07-31
WO2001053506A2 (en) 2001-07-26
BRPI0107737B1 (pt) 2016-11-16
JP2003520044A (ja) 2003-07-02
PT1252322E (pt) 2005-03-31
US20120164108A1 (en) 2012-06-28
EP1252323B1 (en) 2005-12-07
GB2375113A (en) 2002-11-06
CN1418255A (zh) 2003-05-14
EP1252322A2 (en) 2002-10-30
CY2016021I1 (el) 2016-12-14
ES2254359T3 (es) 2006-06-16
US7063835B2 (en) 2006-06-20
AU2694701A (en) 2001-07-31
US8680068B2 (en) 2014-03-25
BR0107737A (pt) 2002-11-19
CY2016020I1 (el) 2016-12-14
EP1252322B1 (en) 2004-11-17
GB2374873A (en) 2002-10-30
US8277818B2 (en) 2012-10-02
IL150678A (en) 2008-12-29
JP6644378B2 (ja) 2020-02-12
AU782659B2 (en) 2005-08-18
LU93100I2 (fr) 2016-08-08
US20120321599A1 (en) 2012-12-20
CY2016020I2 (el) 2016-12-14
JP2003520789A (ja) 2003-07-08
BRPI0107736B1 (pt) 2019-12-17
US20140154216A1 (en) 2014-06-05
AU2001226951B2 (en) 2006-10-05
DE60107203D1 (de) 2004-12-23
US20090220460A1 (en) 2009-09-03
US20070264282A1 (en) 2007-11-15
GB2374873B (en) 2004-05-26
ES2233600T5 (es) 2009-06-22
NL300821I2 (ja) 2016-10-27
IL150677A0 (en) 2003-02-12
HK1047451B (zh) 2005-03-18
US20140154215A1 (en) 2014-06-05
BR0107736A (pt) 2002-11-19
CA2398343A1 (en) 2001-07-26
GB2374873C (en) 2011-07-27
JP4921669B2 (ja) 2012-04-25
JP2012072156A (ja) 2012-04-12
WO2001053506A3 (en) 2002-05-23
HK1047297A1 (en) 2003-02-14
JP6424145B2 (ja) 2018-11-14
EP2177619A1 (en) 2010-04-21
US20200032218A1 (en) 2020-01-30
CY2016021I2 (el) 2016-12-14
US20030091537A1 (en) 2003-05-15
DE60107203T2 (de) 2005-12-01
KR20020080383A (ko) 2002-10-23
IL150678A0 (en) 2003-02-12
GB0219030D0 (en) 2002-09-25
AU2001226951B8 (en) 2006-10-26
JP2017132779A (ja) 2017-08-03
EP1252322B2 (en) 2009-03-04
IL150677A (en) 2008-12-29
CN1250732C (zh) 2006-04-12
CA2398335A1 (en) 2001-07-26
JP2015221813A (ja) 2015-12-10
DE60115600T2 (de) 2006-07-20
DK1252323T3 (da) 2006-04-03
US20030113348A1 (en) 2003-06-19
BRPI0107736B8 (pt) 2021-05-25
EP1568779A1 (en) 2005-08-31
HK1047297B (zh) 2004-10-21
ES2233600T3 (es) 2005-06-16
NL300820I2 (ja) 2016-11-17
BE2016C033I2 (ja) 2020-05-20
KR100802403B1 (ko) 2008-02-13
DK1252322T3 (da) 2005-03-14
HK1047451A1 (en) 2003-02-21
EP1252323A2 (en) 2002-10-30
US7537924B2 (en) 2009-05-26
KR20030032913A (ko) 2003-04-26
US7223593B2 (en) 2007-05-29
US20070003571A1 (en) 2007-01-04
DK1252322T4 (da) 2009-06-08
JP2019048864A (ja) 2019-03-28
BRPI0107737B8 (pt) 2021-05-25
ATE312189T1 (de) 2005-12-15
CA2398335C (en) 2010-12-07
KR100768408B1 (ko) 2007-10-18
ATE282708T1 (de) 2004-12-15
US10301600B2 (en) 2019-05-28
FR16C0026I1 (ja) 2016-07-22
DE60115600D1 (de) 2006-01-12
WO2001053505A3 (en) 2001-12-27
DE60107203T3 (de) 2009-07-23
WO2001053505A2 (en) 2001-07-26
GB2375113B (en) 2004-10-20
CN1425073A (zh) 2003-06-18

Similar Documents

Publication Publication Date Title
FR16C0026I2 (fr) Souches de virus herpetique pour therapie genique
BR0014408A (pt) Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
WO2003082200A3 (en) Potent oncolytic herpes simplex virus for cancer therapy
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
JP2003520044A5 (ja)
DK0675961T3 (da) Behandling af tumorigen sygdom med en modificeret HSV
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
BR9007741A (pt) Protecao contra estados de choque subsequentes a lesoes por rnas de duplo filamento
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.
AR025203A1 (es) Nuevos genes de mixoma para modulacion inmunitaria
AU6301398A (en) Arrestable therapeutic viral agent
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers